These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24161498)

  • 1. Novel continuous flow technology for the development of a nanostructured aprepitant formulation with improved pharmacokinetic properties.
    Angi R; Solymosi T; Ötvös Z; Ordasi B; Glavinas H; Filipcsei G; Heltovics G; Darvas F
    Eur J Pharm Biopharm; 2014 Apr; 86(3):361-8. PubMed ID: 24161498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method.
    Solymosi T; Angi R; Basa-Dénes O; Ránky S; Ötvös Z; Glavinas H; Filipcsei G; Heltovics G
    Eur J Pharm Biopharm; 2015 Aug; 94():135-40. PubMed ID: 26003815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
    Wu Y; Loper A; Landis E; Hettrick L; Novak L; Lynn K; Chen C; Thompson K; Higgins R; Batra U; Shelukar S; Kwei G; Storey D
    Int J Pharm; 2004 Nov; 285(1-2):135-46. PubMed ID: 15488686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements.
    Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Semsey S; Molnár L; Ránky S; Filipcsei G; Heltovics G; Glavinas H
    Int J Pharm; 2017 Oct; 532(1):427-434. PubMed ID: 28919099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states.
    Litou C; Patel N; Turner DB; Kostewicz E; Kuentz M; Box KJ; Dressman J
    Eur J Pharm Sci; 2019 Oct; 138():105031. PubMed ID: 31386891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of aprepitant loaded orally disintegrating films for enhanced pharmacokinetic performance.
    Sharma R; Kamboj S; Singh G; Rana V
    Eur J Pharm Sci; 2016 Mar; 84():55-69. PubMed ID: 26780381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and Pharmacokinetic Study of Aprepitant Solid Dispersions with Soluplus®.
    Liu J; Zou M; Piao H; Liu Y; Tang B; Gao Y; Ma N; Cheng G
    Molecules; 2015 Jun; 20(6):11345-56. PubMed ID: 26102068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect.
    Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Molnár L; McDermott J; Zann V; Church A; Mair S; Filipcsei G; Heltovics G; Glavinas H
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):723-728. PubMed ID: 28776077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation optimization of aprepitant microemulsion-loaded silicated corn fiber gum particles for enhanced bioavailability.
    Kamboj S; Rana V
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1267-82. PubMed ID: 26592754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aprepitant loaded solid preconcentrated microemulsion for enhanced bioavailability: A comparison with micronized Aprepitant.
    Kamboj S; Sharma R; Singh K; Rana V
    Eur J Pharm Sci; 2015 Oct; 78():90-102. PubMed ID: 26165621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of oral bioavailability enhancing formulations during drug discovery.
    Zheng W; Jain A; Papoutsakis D; Dannenfelser RM; Panicucci R; Garad S
    Drug Dev Ind Pharm; 2012 Feb; 38(2):235-47. PubMed ID: 21851310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self nanoemulsifying drug delivery system (SNEDDS) of rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation.
    Balakumar K; Raghavan CV; selvan NT; prasad RH; Abdu S
    Colloids Surf B Biointerfaces; 2013 Dec; 112():337-43. PubMed ID: 24012665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
    Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
    Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel oral delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for poorly water-soluble drug: vinpocetine.
    Lin C; Chen F; Ye T; Zhang L; Zhang W; Liu D; Xiong W; Yang X; Pan W
    Int J Pharm; 2014 Apr; 465(1-2):90-6. PubMed ID: 24530388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs.
    Quinn K; Gullapalli RP; Merisko-Liversidge E; Goldbach E; Wong A; Liversidge GG; Hoffman W; Sauer JM; Bullock J; Tonn G
    J Pharm Sci; 2012 Apr; 101(4):1462-74. PubMed ID: 22213574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects.
    Parrott N; Lukacova V; Fraczkiewicz G; Bolger MB
    AAPS J; 2009 Mar; 11(1):45-53. PubMed ID: 19184451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.